The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

Table 4 Correlations¹ among PROs at baseline and week 12, and change from baseline to week 12

Measure	Baseline			Week 12			Change
	DLQI Total	EQ-5D Index	EQ-5D VAS	DLQI Total	EQ-5D Index	EQ-5D VAS	DLQI Total	EQ-5D Index	EQ-5D VAS
DLQI Total Score	1.00	-0.51	-0.35	1.00	-0.71	-0.58	1.00	-0.53	-0.46
SF-36
Physical Functioning	-0.44	0.58	0.35	-0.41	0.61	0.49	-0.29	0.47	0.32
Role-Physical	-0.45	0.64	0.38	-0.57	0.67	0.50	-0.47	0.51	0.45
Bodily Pain	-0.55	0.73	0.45	-0.61	0.76	0.56	-0.66	0.64	0.53
General Health	-0.24**	0.39	0.47	-0.38	0.59	0.69	-0.33	0.46	0.46
Vitality	-0.31	0.43	0.48	-0.43	0.62	0.60	-0.46	0.37	0.48
Social Functioning	-0.69	0.52	0.46	-0.68	0.74	0.60	-0.68	0.50	0.56
Role-Emotional	-0.41	0.45	0.42	-0.56	0.67	0.53	-0.50	0.41	0.48
Mental Health	-0.44	0.46	0.50	-0.56	0.66	0.67	-0.52	0.49	0.56
Physical Summary Score (PCS)	-0.41	0.64	0.36	-0.46	0.65	0.52	-0.41	0.56	0.39
Mental Summary Score (MCS)	-0.45	0.39	0.49	-0.58	0.66	0.63	-0.59	0.42	0.57
EQ-5D
Index Score	-0.51	1.00	0.39	-0.71	1.00	0.63	-0.53	1.00	0.39
VAS-General Health	-0.35	0.39	1.00	-0.58	0.63	1.00	-0.46	0.39	1.00

¹All correlations were significant at p < 0.001, unless otherwise noted. *p ≤ 0.05, **p ≤ 0.01, ns = non-significant.

ISSN: 1477-7525